Clinic Software← All companies
StageSeed round in progress
Raised$5M (stated goal/raised to date range)
Founded2022
Employees2
LocationReno, NV
About
Sarcomatrix, Inc. is a bio-pharmaceutical company pioneering novel therapeutics that leverage our understanding of muscle biology and tissue regeneration to develop therapies that have potential for broad clinical applicability across multiple disease areas of high unmet need. Our current focus is muscular dystrophy. Muscular dystrophy, a rare disease without a cure, reduces a patient's average life expectancy to 26 years. Our goal is to more than double their life expectancy. Our IP protected vast portfolio of small molecules a7β1 integrin activators and laminin proteins, used as single agents or in combination with cell and gene therapy, may ultimately cure muscular dystrophy.
Product
- Value proposition
- Transforming the treatment landscape for rare muscle diseases and significantly improving quality of life for patients and families through muscle regeneration research and innovative therapies.
Founders
- Dean Burkin Lab — Founder (academic laboratory)
- David Craig — CEO and President
- David Maine — Co-founder
Categories
Products
LAM-111 (therapy)S-969 (drug candidate)SarcoScreen (platform)Sunitinib repurposing
Key features
extracellular matrix biology researchintegrin signalingα7β1 integrin targetinglaminin targetinghigh-throughput screening platform
Technologies
ECM biologyintegrin signalinghigh-throughput screeningdrug discoverymuscle regeneration therapies
Target conditions
muscular dystrophyLAMA2-RDmuscle-wasting diseases
Care settings
clinichospitalhomevirtual
Partnerships
patient advocacy groups and partnerships with familiesindustry partnerships
Traction metrics
$300K investment from Battle Born Venture
Investors
Battle Born VentureResearch AffiliatesPeachscore + Gust Accelerator ProgramUniversity of Nevada, RenoElmstead Partners
News
- Sarcomatrix | LinkedIn · 2025-08-25T00:00:00.000Z
- Sarcomatrix Therapeutics Named Seed-Stage Finalist at BIO International Convention's Start-Up Stadium 2026 · 2026-06-16T14:52:53.000Z
- Sarcomatrix Therapeutics Launches SarcoVista™ AI Platform as Lead Candidate S-969 Advances Toward First-in-Human Studies · 2026-03-31T13:00:00.000Z
- Sarcomatrix Secures $300K Investment from Nevada’s State-Sponsored Venture Capital Program, Battle Born Venture | Sarcomatrix · 2025-08-22T22:38:14.000Z
- Sarcomatrix Therapeutics Launches Regulation D Offering to Advance Novel Oral Muscle Disease Therapy | Sarcomatrix · 2025-04-22T11:10:51.000Z
- Exploring Innovations in Muscle Wasting Disease Treatment · 2025-01-23T08:48:00.000Z
